Durvalumab: all 557 studies that test it

Page 5 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung CancerActive, not recruitingNCT03999710Phase 2
• Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.Status unknownNCT03994393Phase 2
• Study of Olaparib and Durvalumab in IDH-Mutated Solid TumorsActive, not recruitingNCT03991832Phase 2
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1
• Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsWithdrawnNCT03982173Phase 2
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03970616Phase 1/2
• Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT03965468Phase 2
• A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLCTerminatedNCT03963414Phase 1
• A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following ChemoradiationCompletedNCT03955198Phase 2
• A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid TumorsCompletedNCT03946800Phase 1
• Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2
• Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerActive, not recruitingNCT03923270Phase 1
• A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2
• A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid TumorsCompletedNCT03889275Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:Active, not recruitingNCT03875573Phase 2
• Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedNCT03871036Phase 1/2
• Imaging Tumor-infiltrating T-cells in Non-small Cell Lung CancerCompletedNCT03853187Phase 2
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3
• Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingNCT03833440Phase 2
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingNCT03833154Phase 3
• PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCCCompletedNCT03829007Phase 1/2
• hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2
• A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingNCT03819465Phase 1
• Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLCTerminatedNCT03818776Early Phase 1
• Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver MetastasesWithdrawnNCT03802747Phase 1
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerActive, not recruitingNCT03800134Phase 3
• Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell CarcinomaStatus unknownNCT03799744Phase 1
• A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue SarcomaCompletedNCT03798106Phase 2
• Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT03784066Phase 1/2
• Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
• This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)Status unknownNCT03780608Phase 2
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcerCompletedNCT03777813Phase 2
• Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder CancerActive, not recruitingNCT03768570Phase 2
• Efficacy of Durvalumab in Non-muscle-invasive Bladder CancerStatus unknownNCT03759496Phase 2
• GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel StudyCompletedNCT03751761Phase 1/2
• Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.Status unknownNCT03737968Phase 2
• ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1
• Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHNCompletedNCT03726775Phase 2
• FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/PaclitaxelCompletedNCT03723967Phase 2
• Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.Active, not recruitingNCT03704480Phase 2
• Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2
• Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerActive, not recruitingNCT03682068Phase 3
• Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCCWithdrawnNCT03673735Phase 3
• IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid TumorsTerminatedNCT03665129Phase 1
• Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving DurvalumabActive, not recruitingNCT03653052Phase 2
• Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell CarcinomaCompletedNCT03635164Phase 1
• 1st Line Durvalumab in PS 2 NSCLC PatientsActive, not recruitingNCT03620669Phase 2
• A Trial of Radiotherapy and Durvalumab in DLBCL and FLCompletedNCT03610061Phase 1
• Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome SequencingCompletedNCT03608865Phase 2
• Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerActive, not recruitingNCT03594396Phase 1/2
• Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell LungCompletedNCT03589547Phase 2
• Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung CancerStatus unknownNCT03585998Phase 2
• Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerActive, not recruitingNCT03579784Phase 2
• Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic CancerActive, not recruitingNCT03572400Phase 2
• Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerCompletedNCT03544125Phase 1
• Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)CompletedNCT03534492Phase 2
• Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerActive, not recruitingNCT03528694Phase 3
• Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerActive, not recruitingNCT03482102Phase 2
• Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA PatientsCompletedNCT03473574Phase 2
• Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)CompletedNCT03472274Phase 2
• Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersCompletedNCT03452332Phase 1
• Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCCStatus unknownNCT03450967Phase 2
• Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)CompletedNCT03446547Phase 2
• Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerCompletedNCT03430518Phase 1
• Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerWithdrawnNCT03419559Phase 2
• Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCCActive, not recruitingNCT03410615Phase 2
• Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.CompletedNCT03406650Phase 2
• A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell AdenocarcinomasStatus unknownNCT03405454Phase 2
• Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesCompletedNCT03394144Phase 1
• IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaCompletedNCT03381183Phase 1
• Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal CancerStatus unknownNCT03377400Phase 2
• Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.CompletedNCT03356860Phase 1/2
• Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)CompletedNCT03345810Phase 2
• Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)WithdrawnNCT03319316Phase 2
• Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT03317158Phase 1/2
• Study of Durvalumab and Guadecitabine in Advanced Kidney CancerActive, not recruitingNCT03308396Phase 1/2
• Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2
• PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.Status unknownNCT03283943Phase 1
• Immunotherapy and SBRT for Metastatic Head and Neck CarcinomasCompletedNCT03283605Phase 1/2
• Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint InhibitionTerminatedNCT03275597Phase 1
• Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerActive, not recruitingNCT03257761Phase 1
• Radiation Therapy in Combination With Durvalumab for People With Pancreatic CancerActive, not recruitingNCT03245541Phase 1/2
• Durvalumab in DLBCL After Autologous TransplantWithdrawnNCT03241017Phase 2
• A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid TumorsCompletedNCT03238027Phase 1
• Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaWithdrawnNCT03235869Early Phase 1
• Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for CisplatinTerminatedNCT03234153Phase 2
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
• Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCLWithdrawnNCT03212807Phase 2
• A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerCompletedNCT03212469Phase 1/2
• Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRCCompletedNCT03202758Phase 1/2
• A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone PlasmacytomaWithdrawnNCT03196401Phase 1
• Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsActive, not recruitingNCT03158064Phase 2
• Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body RadiotherapyTerminatedNCT03148327Phase 1/2
• Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCWithdrawnNCT03130764Phase 2
• Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid CancerCompletedNCT03122496Phase 1
• Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal CancerCompletedNCT03102047Phase 2
• Synergism of Immunomodulation and Tumor AblationCompletedNCT03101475Phase 2
• MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.CompletedNCT03089645Phase 1

← Durvalumab overview